Success Metrics

Clinical Success Rate
88.9%

Based on 56 completed trials

Completion Rate
89%(56/63)
Active Trials
6(8%)
Results Posted
45%(25 trials)
Terminated
7(9%)

Phase Distribution

Ph not_applicable
1
1%
Ph early_phase_1
2
3%
Ph phase_4
12
15%
Ph phase_1
14
18%
Ph phase_2
21
27%
Ph phase_3
26
33%

Phase Distribution

16

Early Stage

21

Mid Stage

38

Late Stage

Phase Distribution76 total trials
Early Phase 1First-in-human
2(2.6%)
Phase 1Safety & dosage
14(18.4%)
Phase 2Efficacy & side effects
21(27.6%)
Phase 3Large-scale testing
26(34.2%)
Phase 4Post-market surveillance
12(15.8%)
N/ANon-phased studies
1(1.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

56 of 64 finished

Non-Completion Rate

12.5%

8 ended early

Currently Active

6

trials recruiting

Total Trials

79

all time

Status Distribution
Active(7)
Completed(56)
Terminated(8)
Other(8)

Detailed Status

Completed56
unknown8
Terminated7
Recruiting4
Active, not recruiting2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
79
Active
6
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (2.6%)
Phase 114 (18.4%)
Phase 221 (27.6%)
Phase 326 (34.2%)
Phase 412 (15.8%)
N/A1 (1.3%)

Trials by Status

active_not_recruiting23%
unknown810%
completed5671%
not_yet_recruiting11%
recruiting45%
terminated79%
withdrawn11%

Recent Activity

Clinical Trials (79)

Showing 20 of 79 trialsScroll for more
NCT07566351Phase 2

Effect of Roflumilast and Desloratadine as Add-On Therapy in Patients With Rheumatoid Arthritis

Recruiting
NCT06860958Phase 3

Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients

Recruiting
NCT02363335Phase 1

The Role of Phosphodiesterase Inhibitors in Incretin Secretion

Completed
NCT04069312Phase 4

Roflumilast or Azithromycin to Prevent COPD Exacerbations (RELIANCE)

Completed
NCT00242307Phase 2

Efficacy and Safety of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 70 y) (APTA-2217-05)

Completed
NCT00246922Phase 3

Long-term Study of Safety and Efficacy of Roflumilast in Japanese Patients With Bronchial Asthma (20 to 71 y) (APTA-2217-07)

Completed
NCT04636814Phase 3

A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)

Terminated
NCT07352566Phase 4

Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

Not Yet Recruiting
NCT05418049Phase 2

Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge

Active Not Recruiting
NCT07174011Phase 4

Evaluation of the Efficacy and Safety of Oral Roflumilast Versus Intralesional Corticosteroids Injection (ILCs) in the Treatment of Alopecia Areata

Completed
NCT06977711Phase 1

Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL)

Recruiting
NCT06457191Phase 1

Roflumilast and TMS Motor Plasticity

Active Not Recruiting
NCT06440473Phase 4

Visualization of Topical Zoryve vs. Vehicle Using Line Field Optical Coherence Tomography in Healthy Skin

Recruiting
NCT03458546Phase 1

Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma

Completed
NCT05369793Phase 3

Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy

Completed
NCT04108377Phase 1

Phosphodiesterase 4 Inhibitor, Roflumilast, and the Effects of Inhibition in Severe Asthma

Terminated
NCT03381573

Long-term Observational Study of the Safety of Roflumilast

Completed
NCT04549870Phase 2

Efficacy of Roflumilast in the Treatment of Psoriasis

Completed
NCT05884281Phase 1

Efficacy of Roflumilast in Prevention of Peripheral Neuropathy

Unknown
NCT05684744Phase 2

Roflumilast Versus Methotrexate in Psoriasis

Completed

Drug Details

Intervention Type
DRUG
Total Trials
79